• Sisomicin Activity Against Clinical Isolates

  2026-09-15

  This study established a comparative in vitro susceptibility profile for Sisomicin across 565 clinical isolates, showing strong activity against most tested Gram-negative bacilli and several Gram-positive cocci. Its most important translational finding was that gentamicin- and tobramycin-resistant isolates were generally also resistant to Sisomicin, whereas amikacin retained activity against many of these strains.

• Pyruvate Carboxylase, Ferroptosis, and NSCLC

  2026-09-15

  A 2026 Cancer Letters study identifies pyruvate carboxylase as an ATP-linked regulator of ferroptosis resistance in non-small cell lung cancer. Its findings connect PC activity with AMPK suppression, AKT–mTOR-driven lipogenesis, DTX1/USP51-mediated regulation, and improved response to combined ferroptosis-oriented and immune therapy.

• Necrostatin-1 in Host-Pathogen Cell Death Assays

  2026-09-14

  Explore how Necrostatin-1, a RIP1 kinase inhibitor, can help distinguish host necroptosis from parasite-driven cell injury. This article translates a Toxoplasma gondii CRISPR screen into a rigorous host-pathogen assay strategy.

• Exemestane Assay Design: From Target to Phenotype

  2026-09-14

  Exemestane assay design is strongest when it connects aromatase target engagement with estrogen depletion and cellular phenotype. This guide develops a layered workflow for breast cancer research, using the toremifene literature to clarify endocrine assay choices.

• Angiotensin 1/2 (1-6) Research Workflow

  2026-09-13

  Use Angiotensin 1/2 (1-6), the Asp-Arg-Val-Tyr-Ile-His hexapeptide, to build controlled assays for vascular signaling, cardiovascular regulation, renal physiology, and angiotensin-linked receptor biology. Its high aqueous and DMSO solubility also supports practical concentration-response workflows, while recent binding data create a carefully defined bridge to SARS-CoV-2 receptor research.

• Standardized Whole-Blood Immunometabolism Protocol

  2026-09-12

  Zhao and colleagues present a standardized whole-blood stimulation workflow that combines immune challenges, metabolic pathway modulation, and cytokine measurement. The protocol provides a reproducible framework for studying how metabolic state shapes human immune responses while preserving the experimental complexity of blood-based systems.

• E. coli Uracil-DNA Glycosylase (UDG) Guide

  2026-09-11

  E. coli Uracil-DNA Glycosylase (UDG), SKU K1107, excises uracil from single- and double-stranded DNA to support PCR product contamination elimination and in vitro DNA repair research. It is not intended for RNA, oligonucleotides shorter than six bases, or diagnostic and medical applications.

• Annexin V in Translational Apoptosis Research

  2026-09-11

  A thought-leadership framework for using Annexin V to connect phosphatidylserine externalization with apoptosis biology, immune regulation, and translational study design, including implications from a 2025 preeclampsia study.

• Hypoxia and Immunometabolism in Tumor Microenvironments

  2026-09-10

  This 2025 Cancer Letters review presents tumor hypoxia and immunometabolism as a reciprocal system in which oxygen limitation, nutrient competition, and immune-cell dysfunction reinforce an immunosuppressive tumor microenvironment. Its main contribution is a mechanistic framework linking HIF signaling with metabolic reprogramming, immune evasion, and therapeutic design rather than reporting a new experimental intervention.

• Antimycin A4: From Dual Inhibition to Translation

  2026-09-10

  Antimycin A4 is more than a single-pathway probe: its reported ATP-citrate lyase inhibition and mitochondrial respiratory-chain activity create both an opportunity and an interpretive challenge for translational research. This article presents a mechanism-led framework for assay design, validation, product selection, and responsible extrapolation from metabolic phenotypes.

• DRB Workflow for RNA Polymerase II Research

  2026-09-09

  Build controlled transcriptional elongation experiments with DRB, from dose-response design through RNA and protein readouts. This guide connects CDK-dependent RNA polymerase II perturbation with lncRNA translation studies and carefully bounded antiviral applications.

• Aprotinin Workflows for Protease-Sensitive Research

  2026-09-09

  A practical guide to using Aprotinin, or bovine pancreatic trypsin inhibitor, in protease-sensitive protein, cell, and nuclear workflows. It also translates an economical wheat GRO-seq innovation into a cautious, testable strategy for protecting samples without confusing protease control with RNA preservation.

• 7ACC2: A Causal Tool for Tumor Metabolism

  2026-09-08

  7ACC2 is a potent monocarboxylate transporter 1 inhibitor for resolving lactate and pyruvate flux in cancer metabolism research. This article presents an assay-centered framework that connects transporter perturbation with tumor-associated macrophage biology while distinguishing established evidence from testable hypotheses.

• Resiniferatoxin and TRPV1-Positive Afferent Silencing

  2026-09-08

  Szallasi’s 2023 review presents Resiniferatoxin (RTX) as more than an ultra-potent TRPV1 agonist: targeted exposure can first activate and then functionally silence TRPV1-positive sensory afferents. The paper connects receptor pharmacology with preclinical, veterinary, and clinical evidence for pain, neurogenic inflammation, bladder dysfunction, and potential tissue-specific analgesia.

• Y-27632 in ROCK Signaling and Cancer Assays

  2026-09-07

  Y-27632 is a reversible ROCK inhibitor for separating actin-dependent morphology from membrane-protein biology in controlled cell assays. This guide connects stress-fiber perturbation workflows with PD-L1 membrane-remodeling studies, offering practical dosing, controls, and troubleshooting for reproducible cancer biology research.

7930 records 1/529 page Next 12345 下5页 Last page